Download PDF
Thromb Haemost 1975; 33(01): 038-042
DOI: 10.1055/s-0038-1647808
Meeting of the International Committee on Thrombosis and Haemostasis — Symposium on Heparin, Basel, Switzerland, September, 1974
Schattauer GmbH

Heparin Cofactor and Antithrombin[*]

U Abildgaard
1   Medical Department A, Aker Hospital, Oslo 5, Norway
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

 

* Presented at the Symposium on Heparin, Basel, Switzerland, September, 1974.


 

  • References

  • 1 Abildgaard U. Inhibition of the thrombin – fibrinogen reaction by antithrombin III, studied by N-terminal analysis. Scandinavian Journal of Clinical and Laboratory Investigations 20: 207. 1967;
    CrossrefPubMedGoogle Scholar
  • 2 Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scandinavian Journal of Clinical and Laboratory Investigations 1968; a 21: 89.
    CrossrefPubMedGoogle Scholar
  • 3 Abildgaard U. Inhibition of the thrombin-fibrinogen reaction by heparin in the absence of cofactor. Scandinavian Journal of Haematology 5: 432. 1968; b
    PubMedGoogle Scholar
  • 4 Abildgaard U. Thrombin inhibiting action of heparin. Folia Haematol. Leipzig 98: 4. 1972;
    PubMedGoogle Scholar
  • 5 Abildgaard U, Egeberg O. Thrombin inhibitory activity of fraction obtained by gel filtration of antithrombin III deficient plasma. Scandinavian Journal of Haematology 5: 155. 1968;
    PubMedGoogle Scholar
  • 6 Abildgaard U, Ødegård O. R, Kierulf P, Pepper D. S. Influence of platelet factor 4 on inhibited thrombin substrate reactions. Thrombosis Research (In press).; 1974
    Google Scholar
  • 7 Biggs R, Denson K. W. E, Akman N, Borrett R, Hadden M. Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 1970; 19: 287.
    PubMedGoogle Scholar
  • 8 Blombäck B, Blombäck M, Olsson P. Studies on thrombin inactivation in normal plasma, serum and plasma fractions and its relation to heparin. Thrombosis et Diathesis Haemorrhagica 1963; 9: 368.
    PubMedGoogle Scholar
  • 9 Briginshaw G. F, Shanberge J. N. Identification of two distinct heparin cofactors in human plasma. Separation and partial purification. Archives of Biochemistry and Biophysics 161: 683. 1974; a
    PubMedGoogle Scholar
  • 10 Briginshaw G. F, Shanberge J. N. Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factor X. Thrombosis Research 1974; b 4: 463.
    CrossrefPubMedGoogle Scholar
  • 11 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica 1965; 13: 516.
    PubMedGoogle Scholar
  • 12 Fagerhol M. K, Abildgaard U. Immunological studies on antithrombin III. Scandinavian Journal of Haematology 1970; 7: 10.
    PubMedGoogle Scholar
  • 13 Heimburger N. On the proteinase inhibitors of human plasma with special reference to antithrombin. Proceedings of the First International Symposium on Tissue Factor in Homeostasis of the Coagulation ~ Fibrinolysis System. Firenze 1967. 1967
    Google Scholar
  • 14 Henstell H. H, Kligerman M. The nature of heparin antithrombin action. Thrombosis et Diathesis Haemorrhagica 1968; 18: 167.
    PubMedGoogle Scholar
  • 15 Mann Jr L. T, Jensenius J. C, Simonsen M, Abildgaard U. Antithrombin III: Protection against death after injection of thromboplastin. Science 1969; 155: 517.
    PubMedGoogle Scholar
  • 16 Marciniak Ewa. Anticoagulant properties of low density lipoproteins. Federation Proceedings 1974; 33: 217.
    PubMedGoogle Scholar
  • 17 Markwardt F, Walsmann P. Untersuchungen über den Mechanismus der Antithrombinwirkung des Heparins. Hoppe-Seylers Zeitschrift für physiologische Chemie 1959; 317: 64.
    PubMedGoogle Scholar
  • 18 Miller-Andersson M, Borg H, Andersson L.-O. Purification of anti-thrombin III by affinity chromatography. Thrombosis Research (In press).; 1974
    Google Scholar
  • 19 Ødegǻrd O. R, Lie M, Abildgaard U. Heparin cofactor activity measured by an amidolytic method. To be published in Thrombosis Research.
    Google Scholar
  • 20 Porter P, Porter M. C, Shanberge J. N. Heparin cofactor and plasma antithrombin in relation to the mechanism of inactivation of thrombin by heparin. Clinica et Chimica Acta 17 1967; 189.
    CrossrefPubMedGoogle Scholar
  • 21 Rimon A, Shamash Y, Shapiro B. The plasmin inhibitor of human plasma IV. Its action on plasmin, chymotrypsin and thrombin. Journal of Biological Chemistry 1966; 241: 5102.
    PubMedGoogle Scholar
  • 22 Rosenberg R. D, Damus P. S. The purification and mechanism of action of human antithrombin – heparin cofactor. Journal of Biological Chemistry 1973; 248: 6490.
    PubMedGoogle Scholar
  • 23 Steinbuch M, Blatrix C, Josso F. α2-macroglobulin as progressive antithrombin. Nature 1967; 216: 500.
    CrossrefPubMedGoogle Scholar
  • 24 Svendsen L, Blombäck B, Blombäck M, Olsson P. I. Synthetic chro-mogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thrombosis Research 1972; 1: 267.
    CrossrefPubMedGoogle Scholar
  • 25 Wessler S, Yin E. T. Theory and practice of minidose heparin in surgical patients. A status report. Circulation 1973; 47: 671.
    PubMedGoogle Scholar
  • 26 Yin E. T, Wessler S, Stoll JPamela. Biological properties of the naturally occurring plasma inhibitor to activated factor X. Journal of Biological Chemistry 1971; a 246: 3703.
    PubMedGoogle Scholar
  • 27 Yin E. T, Wessler S, Stoll JPamela. Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. Journal of Biological Chemistry 1971; b 246: 3712.
    PubMedGoogle Scholar